Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Y-mAbs Therapeutics Q4 2023 GAAP EPS $(0.020) Beats $(0.210) Estimate, Sales $23.363M Beat $20.955M Estimate

Author: Benzinga Newsdesk | February 29, 2024 05:56pm
Y-mAbs Therapeutics (NASDAQ:YMAB) reported quarterly losses of $(0.020) per share which beat the analyst consensus estimate of $(0.210) by 90.48 percent. This is a 166.67 percent decrease over earnings of $0.030 per share from the same period last year. The company reported quarterly sales of $23.363 million which beat the analyst consensus estimate of $20.955 million by 11.49 percent. This is a 25.71 percent decrease over sales of $31.447 million the same period last year.

Posted In: YMAB


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist